Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 ...

A Foundation for Long-Term AI Transformation The AI Readiness Engagement Framework also serves as a foundation for long-term ...

Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic ...

The BTD designation was granted on the basis of data from a mid-stage trial in which pemvidutide demonstrated statistically ...

The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...

We picked these wireless headphones for gym use for secure fit, sweat resistance, and bass that keeps us moving. In the ...

Pay $5 or more to get Symphony of War: The Nephilim Saga. Pay $10 or more to also receive Disco Elysium, Shadow Gambit: The ...

“The FDA’s Breakthrough Therapy Designation for pemvidutide in MASH reinforces the promise of its clinical profile and potential to address significant unmet needs in this serious, progressive liver ...

January 15, 2026) - Nanjing Leads Biolabs Co., Ltd. (HKE: 9887) ("Leads Biolabs" or the "Company") today announced that Opamtistomig (LBL-024), its core investigational PD-L1/4-1BB bispecific antibody ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for French drugmaker Ipsen’s IPN60340 in combination with venetoclax and azacitidine (Ven-Aza) in first ...

Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit ...

Artificial intelligence is now the dominant force shaping market behaviour in 2026, surpassing traditional macro and policy catalysts, according to Barclays.